Genprex S-1: Lincoln Park to Resell 25M Shares; Oncology Trials Advance

TL;DR

**GNPX's S-1 signals potential dilution from Lincoln Park's 25M share resale, but the underlying financing is a lifeline for its high-risk, high-reward oncology and diabetes pipeline.**

AI Summary

Genprex, Inc. (GNPX) filed an S-1 to register the resale of up to 25,000,000 shares of common stock by Lincoln Park Capital Fund, LLC, stemming from a Purchase Agreement dated June 11, 2025. Genprex will not receive proceeds from Lincoln Park's resale, but may receive up to $10,039,864 from future sales of common stock to Lincoln Park under the Purchase Agreement, in addition to $2,460,136 already received. The company is a clinical-stage gene therapy firm with lead oncology candidate REQORSA, currently in Phase 2a of the Acclaim-1 trial for NSCLC, with interim analysis expected in H1 2026 for 19 patients. The Acclaim-3 trial for ES-SCLC is also in Phase 2 expansion, with interim analysis for 25 patients expected in Q1 2026. Genprex ceased enrollment for the Acclaim-2 trial in August 2024 due to enrollment challenges. The company's diabetes gene therapy candidate, GPX-002, is in preclinical studies, with plans to seek further FDA guidance on IND-enabling studies in H2 2025. The common stock's last reported sale price on Nasdaq on September 12, 2025, was $0.2917 per share.

Why It Matters

This S-1 filing is crucial for investors as it outlines a significant potential for dilution, with Lincoln Park Capital Fund, LLC able to resell up to 25,000,000 shares. While Genprex will not directly benefit from these resales, the underlying Purchase Agreement provides a financing mechanism, potentially injecting up to $10,039,864 into the company, which is vital for funding its clinical trials. The progress of REQORSA in Acclaim-1 and Acclaim-3, particularly the Fast Track and Orphan Drug Designations, could be a competitive differentiator in the crowded oncology space, but the cessation of Acclaim-2 highlights operational challenges. Employees and customers will be impacted by the company's ability to secure funding and advance its pipeline, especially in the highly competitive gene therapy market.

Risk Assessment

Risk Level: high — The risk level is high due to the 'highly speculative' nature of investing in Genprex common stock, as explicitly stated in the filing. The potential resale of up to 25,000,000 shares by Lincoln Park Capital Fund, LLC could lead to significant dilution for existing shareholders. Furthermore, the company is a clinical-stage gene therapy company with no approved products and relies on successful, costly clinical trials, as evidenced by the cessation of the Acclaim-2 trial due to 'enrollment challenges and delays'.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the potential for dilution from the 25,000,000 shares being registered for resale. Monitor the company's cash burn and the actual utilization of the $10,039,864 potential proceeds from the Purchase Agreement, as well as the interim analysis results for Acclaim-1 and Acclaim-3 in H1 2026 and Q1 2026, respectively, as these will be critical catalysts for future valuation.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 25,000,000 — Shares of Common Stock (Maximum shares registered for resale by Lincoln Park Capital Fund, LLC)
• $10,039,864 — Potential Gross Proceeds (Additional aggregate gross proceeds Genprex may receive from sales to Lincoln Park under the Purchase Agreement)
• $2,460,136 — Previously Received Proceeds (Gross proceeds already received from sales to Lincoln Park prior to the S-1 filing date)
• $0.2917 — Common Stock Price (Last reported sale price on Nasdaq on September 12, 2025)
• 0.12 mg/kg — Recommended Phase 2 Dose (RP2D) (Highest dose level of REQORSA approved for Acclaim-1 and Acclaim-3 trials)
• 19 — Patients for Interim Analysis (Number of patients for interim analysis in Phase 2a Acclaim-1 study, expected Q1 2026)
• 25 — Patients for Interim Analysis (Number of patients for futility analysis in Phase 2 Acclaim-3 study, expected Q1 2026)
• 36 months — Prolonged Progression-Free Survival (Duration of response for one patient in Acclaim-1 Phase 1 trial)

Key Players & Entities

• Genprex, Inc. (company) — Registrant and clinical-stage gene therapy company
• Lincoln Park Capital Fund, LLC (company) — Selling stockholder of up to 25,000,000 shares of common stock
• Ryan M. Confer (person) — President, CEO, and CFO of Genprex, Inc.
• The University of Texas MD Anderson Cancer Center (company) — Exclusive worldwide licensor of TUSC2 gene technology
• AstraZeneca (company) — Developer of Tagrisso (osimertinib), used in Acclaim-1 trial
• Merck & Co. (company) — Developer of Keytruda (pembrolizumab), previously used in Acclaim-2 trial
• Genentech, Inc. (company) — Developer of Tecentriq (atezolizumab), used in Acclaim-3 trial
• University of Pittsburgh (company) — Exclusive licensor of diabetes gene therapy technologies
• Food and Drug Administration (FDA) (regulator) — Granted Fast Track Designation for Acclaim-1 and Acclaim-3, and Orphan Drug Designation for Acclaim-3
• Nasdaq Capital Market LLC (regulator) — Listing exchange for Genprex common stock under symbol GNPX

FAQ

Risk Factors

• Reliance on Lincoln Park Capital for Funding [high — financial]: The company's ability to fund its operations and clinical trials is heavily dependent on the Purchase Agreement with Lincoln Park Capital Fund, LLC. Genprex has already received $2,460,136 and may receive up to an additional $10,039,864 from future stock sales to Lincoln Park. This reliance creates a risk if Lincoln Park's willingness or ability to purchase shares changes, or if the stock price remains low, limiting the proceeds Genprex can raise.
• Clinical Trial Enrollment Challenges [high — operational]: Genprex has experienced significant enrollment challenges, leading to the cessation of enrollment for the Acclaim-2 trial in August 2024. This indicates potential difficulties in recruiting patients for its ongoing trials, which could delay timelines, increase costs, and impact the overall development of its lead oncology candidate, REQORSA.
• Uncertainty in Gene Therapy Development [high — regulatory]: As a clinical-stage gene therapy company, Genprex faces inherent risks associated with the development of novel treatments. The success of REQORSA and GPX-002 is not guaranteed, and regulatory hurdles, including FDA approvals, are significant. The company is still seeking further FDA guidance on IND-enabling studies for GPX-002, highlighting the early stage and inherent uncertainties.
• Low Stock Price and Market Perception [medium — market]: The company's common stock was trading at $0.2917 per share on September 12, 2025. This low stock price may reflect market concerns about the company's progress, financial health, or the viability of its pipeline, potentially impacting its ability to raise capital through equity offerings beyond the Lincoln Park agreement.
• Limited Operating History and Profitability [high — financial]: Genprex is a clinical-stage company with no history of product sales or profitability. Its financial resources are primarily derived from financing activities, such as the Lincoln Park agreement. The company will require substantial additional funding to advance its pipeline through clinical trials and achieve commercialization.

Industry Context

Genprex operates in the highly competitive and rapidly evolving gene therapy sector, focusing on oncology and metabolic diseases. The industry is characterized by significant R&D investment, long development timelines, and high regulatory hurdles. Success hinges on demonstrating clinical efficacy and safety, navigating complex manufacturing processes, and securing substantial funding for late-stage trials and commercialization.

Regulatory Implications

As a gene therapy developer, Genprex faces stringent regulatory oversight from the FDA. The success of its pipeline, particularly REQORSA and GPX-002, is contingent upon meeting rigorous safety and efficacy standards throughout the clinical trial process and obtaining marketing approval. Delays or setbacks in regulatory pathways, such as IND acceptance or trial approvals, pose significant risks.

What Investors Should Do

1. Monitor Q1 2026 Interim Trial Results
2. Assess Funding Runway and Future Capital Needs
3. Evaluate Clinical Trial Enrollment Progress
4. Track Progress on GPX-002 Development

Key Dates

• 2025-06-11: Purchase Agreement with Lincoln Park Capital Fund, LLC — Establishes a framework for potential future equity financing, providing up to $10,039,864 in additional proceeds, in addition to the $2,460,136 already received.
• 2025-08-01: Enrollment Cessation for Acclaim-2 Trial — Highlights significant patient recruitment challenges, raising concerns about the feasibility and timelines of ongoing clinical development.
• 2025-09-12: Last Reported Sale Price of Common Stock — The stock traded at $0.2917, indicating a low market valuation and potential challenges in raising capital through public offerings.
• 2026-01-01: Expected Interim Analysis for Acclaim-3 Trial — Provides a near-term catalyst for investors, with results from 25 patients in the ES-SCLC trial expected to inform the drug's potential.
• 2026-01-01: Expected Interim Analysis for Acclaim-1 Trial — Offers another near-term catalyst, with interim results from 19 patients in the NSCLC trial expected to provide insights into REQORSA's efficacy.
• 2025-07-01: Expected FDA Guidance on GPX-002 IND-enabling studies — Marks a potential step forward for the diabetes gene therapy candidate, contingent on successful preclinical studies and regulatory feedback.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (This S-1 filing specifically registers the resale of shares by Lincoln Park Capital, providing transparency on potential dilution and the company's financing arrangements.)

Clinical-Stage

Refers to a biotechnology or pharmaceutical company whose drug candidates are undergoing clinical trials in humans, but have not yet received regulatory approval for marketing. (Genprex is a clinical-stage company, meaning its lead product candidates are still in development and face significant risks before potential commercialization.)

IND-enabling studies

Preclinical studies required by regulatory agencies like the FDA to assess the safety and efficacy of a drug candidate before it can be tested in human clinical trials. (Genprex's plan to seek FDA guidance on IND-enabling studies for GPX-002 indicates the early stage of this diabetes therapy candidate.)

NSCLC

Non-Small Cell Lung Cancer, the most common type of lung cancer. (Genprex's lead oncology candidate, REQORSA, is being evaluated in Phase 2a trials for NSCLC (Acclaim-1).)

ES-SCLC

Extensive-Stage Small Cell Lung Cancer, a more aggressive form of lung cancer. (REQORSA is also being studied in Phase 2 trials for ES-SCLC (Acclaim-3).)

Interim Analysis

A planned review of data collected during a clinical trial before the trial is completed. It helps determine if the trial should continue, be modified, or stopped early. (Interim analyses for both the Acclaim-1 and Acclaim-3 trials are expected in early 2026, providing key data points for investors.)

Purchase Agreement

A contract between a buyer and a seller that details the terms and conditions of a sale. In this context, it's an agreement for Lincoln Park Capital to purchase Genprex's common stock. (This agreement is crucial for Genprex's financing, allowing for potential capital raises but also involving resale of shares by the investor.)

Year-Over-Year Comparison

This S-1 filing does not provide comparative financial data from a previous filing. However, it highlights a significant financing event with Lincoln Park Capital, involving the registration of 25,000,000 shares for resale and potential future capital raises totaling up to $10,039,864. The filing also underscores recent operational challenges, such as the cessation of enrollment in the Acclaim-2 trial, and provides updated timelines for key clinical trial milestones in 2026.

Key Financial Figures

• $0.001 — 0 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund
• $10,039,864 — ckholder. However, we may receive up to $10,039,864 (in addition to the $2,460,136 previous
• $2,460,136 — e up to $10,039,864 (in addition to the $2,460,136 previously received from sales made pur
• $0.2917 — ock on Nasdaq on September 12, 2025 was $0.2917 per share. Investing in our common sto
• $6,895,947 — M program for aggregate net proceeds of $6,895,947. Nasdaq Compliance Matters As previo
• $1,391,195 — "), because our stockholders' equity of $1,391,195 as reported in our Quarterly Report on
• $2.5 m — 2025 was below the required minimum of $2.5 million, and because, as of August 19, 20
• $1.00 m — e have not regained compliance with the $1.00 minimum bid price requirement set forth i
• $1.00 — ties to maintain a minimum bid price of $1.00 per share and, as previously disclosed,

Filing Documents

• gnpx20250909_s1.htm (S-1) — 444KB
• ex_860433.htm (EX-5.1) — 7KB
• ex_860434.htm (EX-23.1) — 2KB
• ex_860435.htm (EX-FILING FEES) — 25KB
• lowensandlogo.jpg (GRAPHIC) — 16KB
• 0001437749-25-028955.txt ( ) — 619KB
• ex_860435_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 10 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 14 THE LINCOLN PARK TRANSACTION 16

DILUTION

DILUTION 23 SELLING STOCKHOLDER 24 PLAN OF DISTRIBUTION 25

DESCRIPTION OF SECURITIES TO BE REGISTERED

DESCRIPTION OF SECURITIES TO BE REGISTERED 27 LEGAL MATTERS 30 EXPERTS 30 WHERE YOU CAN FIND MORE INFORMATION 30 INCORPORATION OF DOCUMENTS BY REFERENCE 30 ABOUT THIS PROSPECTUS The registration statement we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein before making your investment decision. You should rely only on the information provided in this prospectus or any amendment thereto. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading "Where You Can Find More Information." The selling stockholder named in this prospectus may sell up to 25,000,000 shares of our common stock previously issued and issuable pursuant to the Purchase Agreement from time to time. This prospectus also covers any shares of common stock that may become issuable as a result of share splits, share dividends, or similar transactions. We have agreed to pay the expenses incurred in registering these shares, including legal and accounting fees. We have not, and the selling stockholder has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus, the documents incorporated by reference herein or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take n

View Full Filing

View this S-1 filing on SEC EDGAR